LB-P6 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 1 |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05053165 (ClinicalTrials.gov) | January 4, 2022 | 16/9/2021 | A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants | A Phase 1, Randomised, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of LB-P6 or LB-P8 in Healthy Participants | Rheumatoid Arthritis;Non-Alcoholic Steatohepatitis | Drug: LB-P6;Drug: LB-P8;Drug: Placebo | LISCure Biosciences | NULL | Completed | 18 Years | 65 Years | All | 31 | Phase 1 | Australia |